Table 3.

Univariate analyses on risk factors associated with 7-year CIR

Estimates, %95% CIP value
Diagnosis    
Acute lymphoblastic leukemia 22 14-31 <.01 
Acute myeloid leukemia 31 25-38  
MDS 10 0-21  
Secondary leukemia    
No 26 20-32 .32 
Yes 31 17-45  
Cytogenetics∗     
Good risk 21 6-37 .74 
Intermediate risk 29 22-36  
Poor risk 28 18-38  
Disease status at transplant    
CR1 or CR2 26 20-33 .71 
CR >2 or active disease 29 15-43  
Recipientsex    
Male 24 17-31 .22 
Female 29 22-36  
Recipient body weight, kg    
<70 31 24-38 .043 
≥70 23 17-29  
Recipient age at transplant, y    
<18 20 8-31 .40 
≥18 27 22-32  
<40 24 16-32 .40 
≥40 28 22-35  
Year of transplant    
<2012 32 25-39 <.01 
≥2012 20 14-26  
Time from diagnosis to transplant, mo    
<12 24 18-30 .87 
≥12 28 20-36  
Recipient CMV serology    
Negative 26 19-32 .93 
Positive 26 19-32  
No. of HLA mismatches between the recipient and the WU†     
<2 28 16-39 .96 
≥2 26 21-31  
<3 25 17-33 .56 
≥3 27 21-33  
Conditioning regimen intensity    
Myeloablative 20 13-26 .022 
Reduced intensity 31 16-47  
Total body irradiation    
No 25 18-32 .98 
Yes 26 21-31  
TNC dose at collection    
<5.37 × 107 28 21-35 .82 
≥5.37 × 107 25 19-32  
CD34+ cell dose at collection    
<2.20 × 105 28 21-35 .87 
≥2.20 × 105 26 19-33  
PT-LU shared mismatch against the WU (any locus)    
No 28 22-35 .44 
Yes 24 17-30  
PT-LU HLA class I shared mismatch against the WU (HLA-A, -B, or -C)    
No 30 25-35 .11 
Yes 21 14-27  
PT-LU HLA-A shared mismatch against the WU    
No 28 23-33 .048 
Yes 16 7-25  
PT-LU HLA-B shared mismatch against the WU    
No 28 23-33 .079 
Yes 15 5-24  
PT-LU HLA-C shared mismatch against the WU    
No 27 22-32 .51 
Yes 22 12-31  
PT-LU HLA-DRB1 shared mismatch against the WU    
No 26 20-32 .96 
Yes 28 13-42  
Grade 2-4 acute GVHD    
No 36 28-43 <.001 
Yes 17 12-23  
Grade 3-4 acute GVHD    
No 28 23-34 .057 
Yes 17 7-26  
Chronic GVHD (limited + extensive)    
No 30 23-37 .069 
Yes 22 15-29  
Extensive chronic GVHD    
No 28 23-34 .10 
Yes 18 8-28  
Estimates, %95% CIP value
Diagnosis    
Acute lymphoblastic leukemia 22 14-31 <.01 
Acute myeloid leukemia 31 25-38  
MDS 10 0-21  
Secondary leukemia    
No 26 20-32 .32 
Yes 31 17-45  
Cytogenetics∗     
Good risk 21 6-37 .74 
Intermediate risk 29 22-36  
Poor risk 28 18-38  
Disease status at transplant    
CR1 or CR2 26 20-33 .71 
CR >2 or active disease 29 15-43  
Recipientsex    
Male 24 17-31 .22 
Female 29 22-36  
Recipient body weight, kg    
<70 31 24-38 .043 
≥70 23 17-29  
Recipient age at transplant, y    
<18 20 8-31 .40 
≥18 27 22-32  
<40 24 16-32 .40 
≥40 28 22-35  
Year of transplant    
<2012 32 25-39 <.01 
≥2012 20 14-26  
Time from diagnosis to transplant, mo    
<12 24 18-30 .87 
≥12 28 20-36  
Recipient CMV serology    
Negative 26 19-32 .93 
Positive 26 19-32  
No. of HLA mismatches between the recipient and the WU†     
<2 28 16-39 .96 
≥2 26 21-31  
<3 25 17-33 .56 
≥3 27 21-33  
Conditioning regimen intensity    
Myeloablative 20 13-26 .022 
Reduced intensity 31 16-47  
Total body irradiation    
No 25 18-32 .98 
Yes 26 21-31  
TNC dose at collection    
<5.37 × 107 28 21-35 .82 
≥5.37 × 107 25 19-32  
CD34+ cell dose at collection    
<2.20 × 105 28 21-35 .87 
≥2.20 × 105 26 19-33  
PT-LU shared mismatch against the WU (any locus)    
No 28 22-35 .44 
Yes 24 17-30  
PT-LU HLA class I shared mismatch against the WU (HLA-A, -B, or -C)    
No 30 25-35 .11 
Yes 21 14-27  
PT-LU HLA-A shared mismatch against the WU    
No 28 23-33 .048 
Yes 16 7-25  
PT-LU HLA-B shared mismatch against the WU    
No 28 23-33 .079 
Yes 15 5-24  
PT-LU HLA-C shared mismatch against the WU    
No 27 22-32 .51 
Yes 22 12-31  
PT-LU HLA-DRB1 shared mismatch against the WU    
No 26 20-32 .96 
Yes 28 13-42  
Grade 2-4 acute GVHD    
No 36 28-43 <.001 
Yes 17 12-23  
Grade 3-4 acute GVHD    
No 28 23-34 .057 
Yes 17 7-26  
Chronic GVHD (limited + extensive)    
No 30 23-37 .069 
Yes 22 15-29  
Extensive chronic GVHD    
No 28 23-34 .10 
Yes 18 8-28  
∗

Cytogenetics available for 308 patients (80%).

†

Number of HLA mismatches between the recipient and the WU according to low-resolution typing for HLA-A, HLA-B, and HLA-C; and high-resolution typing for HLA-DRB1.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal